Clinical Trials

Find a Doctor Our Locations Awards and Accreditation

Home › Research › Trials

A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma.

A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis

Phase II Study of Nivolumab/Ipilimumab plus Cabozantinib in Patients with Unresectable Advanced Melanoma

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-Risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCCC) (KEYNOTE-630)

A Phase IB Trial Of Neoadjuvant AMG 232 Concurrent With Preoperative Radiotherapy In Wild-Type P53 Soft Tissue Sarcoma (STS)

A Phase II Randomized Study of Adjuvant vs. Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High Risk Melanoma.

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma